-
-
-$0.69 EPS Expected for Nektar Therapeutics
$NKTR This Quarter http://zpr.io/tujWW -
-
Nice...... also may want to keep an eye on
$NKTR ..... something has this thing moving. -
$NKTR now we commence the move back up
looking out to May -
Morning highest % above OR 30-min high, Up/Avg Gain of today's four 30-min bars, G/L % in previous 30-Min & Trading range % (Min $5, Vol > 750K, Opt Vol in any strike > 250):
$ATI$TEVA$SDC$INSG$LITE$CRON$LK$LB$MIK$DELL$WORK$MAC$BYND$AA$NKTR$CRWD$NTNX$TTD$ENPHpic.twitter.com/C9flz0UdUN
-
Brokerages Anticipate Nektar Therapeutics
$NKTR Will Announce Quarterly Sales of $26.34 Million http://baseballnewssource.com/?p=3940625 -
$26.34 Million in Sales Expected for Nektar Therapeutics
$NKTR This Quarter http://americanbankingnews.com/?p=13273131#stocks -
$NKTR Nektar call volume above normal and directionally bullish pic.twitter.com/FiZIuQHdp1
-
$NKTR Two bempeg manuscripts published and a Mizuho upgrade equal nice movement, on strong volume, it seems. Shares still buyable, imho. /long. -
Watching
$NKTR this morning -
$NKTR Mizuho analyst Difei Yang upgraded Nektar Therapeutics to Buy from Neutral with a price target of $35, up from $21 -
Mizuho Reaffirms Buy Rating for Nektar Therapeutics
$NKTR http://theenterpriseleader.com/?p=2613347 -
Mizuho upgrades Nektar to Buy on 'good risk/reward' into cancer data
$NKTR http://dlvr.it/RPH8hg
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.
Sell (-22%) for
Buy (11%) for